View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2020

Petrovax begins dosing in Phase III trial of CanSino’s Covid-19 vaccine

Russia's Petrovax Pharm has started dosing participants in a Phase III clinical trial of Ad5-nCoV Covid-19 vaccine candidate developed by China-based CanSino Biologics and Beijing Institute of Biotechnology, Academy of Military Medical Science. 

Russia’s Petrovax Pharm has started dosing participants in a Phase III clinical trial of Ad5-nCoV Covid-19 vaccine candidate developed by China-based CanSino Biologics and Beijing Institute of Biotechnology, Academy of Military Medical Science.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The first group of participants were vaccinated at medical centres in Moscow, in alliance with contract research organisation OCT Clinical.

Currently, the subjects are doing well, said Petrovax. They will be monitored for the initial 28 days post vaccination and will receive four interim face-to-face examinations at treatment centres.

During this period, the vaccinated participants are expected to develop an antibody and cellular immune response to Covid-19. The subjects will then undergo a control analysis after six months.

Petrovax Pharm president Mikhail Tsyferov said: “This is an important step for us that will bring us closer to the earliest possible resolution of the coronavirus situation, not only in Russia, but throughout the world.

“Thanks to the efforts of our team and partners, we are optimistic about the continuation of a large-scale study that can offer an effective means to protect the population against Covid-19.”

The company is enroling additional participants at other medical centres in Russia. It received approval for the Phase III trial earlier this month.

Ad5-nCoV vaccine is based on an adenoviral vector platform and carries the S-protein of the coronavirus. The vector acts as a delivery vehicle and the S-protein provides genetic information to potentially elicit an immune response.

Following registration in the Russian Federation, Petrovax expects to manufacture more than four million doses of the vaccine per month this year at its Moscow Region facilities.

Production may increase to ten million doses per month next year, owing to the planned expansion of capacity, added Petrovax.

The company will have sole rights to supply the vaccine in Russia and the CIS countries.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena